We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

VITdAL@ICU - Correction of Vitamin D Deficiency in Critically Ill Patients (VITdAL@ICU)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01130181
First Posted: May 25, 2010
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Harald Dobnig, MD, Medical University of Graz
May 21, 2010
May 25, 2010
October 12, 2017
May 2010
September 2012   (Final data collection date for primary outcome measure)
Length of hospital stay [ Time Frame: maximum 6 months ]
The length of hospital stay will be compared between the two groups (starting from application of the study medication; end is defined as death of the patient or hospital discharge) Survivors and non-survivors will also be analysed separately. Stay in rehabilitation facilities will not be counted.
Same as current
Complete list of historical versions of study NCT01130181 on ClinicalTrials.gov Archive Site
  • 25(OH)D levels [ Time Frame: maximum 6 months ]
    serum 25(OH)D levels will be measured on day 0, 3 and 7
  • calcium levels [ Time Frame: maximum 6 months ]
    serum calcium levels will be measured on day 0, 3 and 7
  • length of ICU stay starting from application of study medication [ Time Frame: until patient's death or referral to another ward ]
  • duration of mechanical ventilation [ Time Frame: starting from application of study medication ]
    duration of mechanical ventilation including CPAP/mask ventilation
  • hospital mortality, 28-day mortality, 6 month-mortality [ Time Frame: maximum 6 months ]
Same as current
Not Provided
Not Provided
 
VITdAL@ICU - Correction of Vitamin D Deficiency in Critically Ill Patients
Correction of Vitamin D Deficiency in Critically Ill Patients: a Randomized, Double-blind, Placebo-controlled Trial ("VITDAL@ICU")

Study hypothesis:

High-dose vitamin D leads to a shorter hospital stay in critically ill patients

Vitamin D deficient patients will be randomized to receive either 540,000 IU cholecalciferol or placebo.

Inclusion criteria

  • Age ≥18 years
  • expected ICU stay ≥48 hours
  • vitamin D deficiency: 25(OH)D ≤ 20 ng/ml
  • feasibility of study drug application via nasogastric tube in cases where oral food intake is not possible

Exclusion criteria

  • moribund patient expected to die within 24 hours
  • hypercalcaemia (total calcium >2.65 OR ion. calcium >1.35 mmol/l)
  • severely impaired gastrointestinal motility (ileus, residual gastric volume > 400 ml)
  • known history of recent kidney stones (≤ 1 year)
  • known granulomatous diseases (tuberculosis, sarcoidosis)
  • pregnancy

Primary endpoint

  • hospital stay (hours; starting from ICU admission) Secondary endpoints
  • percentage of patients with 25(OH)D ≥ 30 ng/ml at day 7
  • serum calcium; phosphorus; 25(OH)D; 1,25(OH)D; PTH; osteocalcin; bALP; TRAP; urinary calcium
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
  • Critical Illness
  • Vitamin D Deficiency
  • Drug: Cholecalciferol
    loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU
  • Drug: Placebo
    Matching placebo
    Other Name: herbal oil
  • Experimental: Cholecalciferol
    Intervention: Drug: Cholecalciferol
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
480
September 2012
September 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age ≥18 years
  • expected ICU stay ≥48 hours
  • vitamin D deficiency: 25(OH)D ≤ 20 ng/ml
  • feasibility of study drug application via nasogastric tube in cases where oral food intake is not possible

Exclusion Criteria:

  • moribund patient expected to die within 24 hours
  • hypercalcaemia (total calcium >2.65 OR ion. calcium >1.35 mmol/l)
  • severely impaired gastrointestinal motility (ileus, residual gastric volume > 400 ml)
  • known history of recent kidney stones (≤ 1 year)
  • known granulomatous diseases (tuberculosis, sarcoidosis)
  • pregnancy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
 
NCT01130181
VITdAL@ICU - 19022010
Yes
Not Provided
Not Provided
Harald Dobnig, MD, Medical University of Graz
Harald Dobnig, MD
Not Provided
Principal Investigator: Harald Dobnig, MD Medical University of Graz, Austria
Medical University of Graz
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP